AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
|Articles|October 1, 1998
Supplements and Featured Publications
- Clinical and Economic Considerations of Antimicrobial Use
- Volume 4
- Issue 11 Suppl
Optimizing Antimicrobial Therapy and Emerging Pathogens
Author(s)David P. Nicolau, PharmD
Advertisement
Articles in this issue
about 28 years ago
Participating Facultyabout 28 years ago
Introductionabout 28 years ago
Mechanisms and Current Rates of Resistanceabout 28 years ago
Influence of Antibiotics on the Normal Floraabout 28 years ago
Therapeutic Pathways for Antimicrobial Use: General Overviewabout 28 years ago
Therapeutic Pathways for Antimicrobial Use: Pediatric Issuesabout 28 years ago
Pharmacoeconomic Impact of Appropriate Clinical Pathwaysabout 28 years ago
CME QuizAdvertisement
Related to this article
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5